Nuage Therapeutics has announced the closing of a financing round by Sabadell Asabys, the investment vehicle managed by Asabys Partners, members of CataloniaBio & HealthTech. With this injection of capital, the spin-off will start its work discovering drugs aimed at therapeutic targets currently considered undruggable.
Based at the Barcelona Science Park, Nuage Therapeutics uses a proprietary assay to discover new drugs for the treatment of castration-resistant prostate cancer. Further pre-clinical programs will be announced in the coming months. The scientists behind Nuage Therapeutics have spent years investigating target proteins currently considered undruggable due to their unique structural properties.
The financing provided by Sabadell Asabys will be added to other resources under negotiation with local and international funds until the closing of a financing round where Asabys will also participate. Clara Campàs, founding partner of Asabys, says, “This operation reflects the strategy followed by Sabadell Asabys to invest in early-stage initiatives of outstanding scientific quality, like Nuage Therapeutics. This technology allows drug discovery in a totally different way than what we have seen until now.”
Asabys Partners, a venture capital manager firm specialized in the healthcare sector, founded by Josep Ll. Sanfeliu and Clara Campàs and participated by Alantra, concludes with this its first investment health fund. This first investment vehicle was launched in 2019 and is backed by the Banc Sabadell as reference investor, with a size of more than €86M to invest in healthcare companies across three verticals: biotech, medtech and digital therapeutics.
Photo: Clara Campàs (Managing Partner, Asabys), Francesc Posas (Director, IRB), Emilià Pola (Director, ICREA), Xavier Salvatella, Mateusz Biesaga i Denes Hnisz (Co-founders, Nuage Therapeutics).
Comments